Table 2. Meta-analysis outcomes at 30-day follow-up.
| Outcome | Studies | Event rate | Odds ratio (95% CI) | I2 | Chi2 | Intergroup difference P value | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| TAVR | SAVR | Overall | Low-risk | Intermediate-risk | ||||||
| All-cause mortality | 6 | 69/3,275 (2.1%) | 74/3,120 (2.4%) | 0.88 (0.60–1.31) | 0.51 (0.24–1.11) | 1.04 (0.71–1.51) | 11% | 5.6 | 0.11 | |
| Cardiac mortality | 6 | 60/3,275 (1.8%) | 64/3,120 (2.0%) | 0.92 (0.64–1.31) | 0.52 (0.24–1.13) | 1.07 (0.71–1.60) | 0% | 4.04 | 0.11 | |
| Stroke | 6 | 116/3,275 (3.5%) | 145/3,120 (4.7%) | 0.74 (0.52–1.05) | 0.67 (0.29–1.54) | 0.74 (0.48–1.15) | 30% | 7.09 | 0.83 | |
| Major bleeding | 5 | 261/3,241 (8.1%) | 706/3,084 (22.9%) | 0.32 (0.11–0.91) | 0.25 (0.11–0.56) | 0.45 (0.05–3.84) | 97% | 134.4 | 0.61 | |
| Acute kidney injury | 6 | 39/3,275 (1.2%) | 102/3,120 (3.3%) | 0.37 (0.25–0.54) | 0.30 (0.13–0.67) | 0.40 (0.26–0.62) | 0% | 3.91 | 0.53 | |
| Atrial fibrillation | 5 | 303/3,241 (9.3%) | 1,072/3,084 (34.8%) | 0.17 (0.12–0.24) | 0.13 (0.10–0.18) | 0.23 (0.16–0.34) | 80% | 19.95 | 0.02 | |
| Permanent pacemaker | 5 | 513/3,241 (15.8%) | 182/3,084 (5.9%) | 3.31 (1.64–6.66) | 4.32 (1.51–12.36) | 2.51 (0.67–9.37) | 92% | 48.22 | 0.53 | |
| Major vascular complications | 5 | 179/3,241(5.5%) | 91/3,084 (3.0%) | 2.09 (1.18–3.71) | 1.39 (0.87–2.22) | 2.91 (0.86–9.83) | 70% | 13.27 | 0.27 | |
| Mod-severe paravalvular regurgitation | 5 | 66/2,917 (2.2%) | 8/2,531 (0.3%) | 5.97 (2.67–13.34) | 2.57 (0.34–19.66) | 7.15 (3.24–15.77) | 8% | 4.37 | 0.36 | |
CI, confidence interval; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.